Tana Machackova1, Karolina Trachtova1, Vladimir Prochazka2, Tomas Grolich2, Martina Farkasova2, Lukas Fiala3, Roman Sefr3, Igor Kiss4, Matej Skrovina5,6, Michal Dosoudil5, Ioana Berindan-Neagoe7, Marek Svoboda4, Ondrej Slaby8,9, Zdenek Kala10. 1. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 2. Department of Surgery, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3. Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 4. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 5. Department of Surgery, Hospital & Oncological Centre Novy Jicin, Novy Jicin, Czech Republic. 6. Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. 7. MEDFUTURE-Research Center for Advanced Medicine, University of Medicine and Pharmacy Iuliu-Hatieganu, Cluj-Napoca, Romania. 8. Central European Institute of Technology, Masaryk University, Brno, Czech Republic Kala.Zdenek@fnbrno.cz on.slaby@gmail.com. 9. Department of Pathology, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. 10. Department of Surgery, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic Kala.Zdenek@fnbrno.cz on.slaby@gmail.com.
Abstract
BACKGROUND/AIM: Rectal cancer accounts for approximately one-third of all colorectal cancers. Currently, the standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) with capecitabine or 5-fluorouracil followed by curative surgery. Unfortunately, only 20% of patients with LARC present complete pathological response after CRT, whereas in 20-40% cases the response is poor or absent. The aim of our study was to evaluate whether microRNAs (miRNAs) in tumor biopsy specimen have the potential to predict therapeutic response in LARC patients. PATIENTS AND METHODS: In total 87 LARC patients treated by CRT were enrolled in our prospective study. To identify predictive miRNAs, we used small RNA sequencing in 40 tumor biopsy samples of LARC patients (20 responders, 20 non-responders) and qPCR validation of selected miRNA candidates. RESULTS: In the discovery phase of the study, we identified 69 miRNAs to have significantly different expression between the group of responders (TRG 1,2) and a group of non-responders (TRG 4,5) to neoadjuvant CRT. Among these miRNAs, 48 showed a lower expression and 21 showed higher expression in tumor tissues from poorly responding LARC patients. Five miRNAs were selected for validation, but only miR-487a-3p was confirmed to have a significantly higher expression in the tumor biopsy specimens of non-responders to neoadjuvant CRT (p<0.0006, AUC=0.766). Gene Ontology (GO) clustering and pathway enrichment analysis of the miR-487a-3p mRNA targets, revealed potential mechanisms behind miR-487a-3p roles in chemoradioresistance (e.g. TGF-beta signaling pathway, protein kinase activity, double-stranded DNA binding, or microRNAs in cancer). CONCLUSION: By combination of miRNA expression profiling and integrative computational biology we identified miR-487a-3p as a potential predictive biomarker of CRT response in LARC patients. Copyright
BACKGROUND/AIM: Rectal cancer accounts for approximately one-third of all colorectal cancers. Currently, the standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) with capecitabine or 5-fluorouracil followed by curative surgery. Unfortunately, only 20% of patients with LARC present complete pathological response after CRT, whereas in 20-40% cases the response is poor or absent. The aim of our study was to evaluate whether microRNAs (miRNAs) in tumor biopsy specimen have the potential to predict therapeutic response in LARCpatients. PATIENTS AND METHODS: In total 87 LARCpatients treated by CRT were enrolled in our prospective study. To identify predictive miRNAs, we used small RNA sequencing in 40 tumor biopsy samples of LARCpatients (20 responders, 20 non-responders) and qPCR validation of selected miRNA candidates. RESULTS: In the discovery phase of the study, we identified 69 miRNAs to have significantly different expression between the group of responders (TRG 1,2) and a group of non-responders (TRG 4,5) to neoadjuvant CRT. Among these miRNAs, 48 showed a lower expression and 21 showed higher expression in tumor tissues from poorly responding LARCpatients. Five miRNAs were selected for validation, but only miR-487a-3p was confirmed to have a significantly higher expression in the tumor biopsy specimens of non-responders to neoadjuvant CRT (p<0.0006, AUC=0.766). Gene Ontology (GO) clustering and pathway enrichment analysis of the miR-487a-3p mRNA targets, revealed potential mechanisms behind miR-487a-3p roles in chemoradioresistance (e.g. TGF-beta signaling pathway, protein kinase activity, double-stranded DNA binding, or microRNAs in cancer). CONCLUSION: By combination of miRNA expression profiling and integrative computational biology we identified miR-487a-3p as a potential predictive biomarker of CRT response in LARCpatients. Copyright
Authors: Magdalena Zurawek; Agnieszka Dzikiewicz-Krawczyk; Katarzyna Izykowska; Iwona Ziolkowska-Suchanek; Bogda Skowronska; Maria Czainska; Marta Podralska; Piotr Fichna; Grzegorz Przybylski; Marta Fichna; Jerzy Nowak Journal: Diabetes Res Clin Pract Date: 2018-05-31 Impact factor: 5.602
Authors: Margarita González-Vallinas; Manuel Rodríguez-Paredes; Marco Albrecht; Carsten Sticht; Damian Stichel; Julian Gutekunst; Adriana Pitea; Steffen Sass; Francisco J Sánchez-Rivera; Justo Lorenzo-Bermejo; Jennifer Schmitt; Carolina De La Torre; Arne Warth; Fabian J Theis; Nikola S Müller; Norbert Gretz; Thomas Muley; Michael Meister; Darjus F Tschaharganeh; Peter Schirmacher; Franziska Matthäus; Kai Breuhahn Journal: Mol Cancer Res Date: 2018-01-12 Impact factor: 5.852
Authors: Jochen Gaedcke; Marian Grade; Jordi Camps; Rolf Søkilde; Bogumil Kaczkowski; Aaron J Schetter; Michael J Difilippantonio; Curtis C Harris; B Michael Ghadimi; Søren Møller; Tim Beissbarth; Thomas Ried; Thomas Litman Journal: Clin Cancer Res Date: 2012-07-31 Impact factor: 12.531
Authors: Cristina Caramés; Ion Cristobal; Víctor Moreno; Juan P Marín; Paula González-Alonso; Blanca Torrejón; Pablo Minguez; Ana Leon; José I Martín; Roberto Hernández; Manuel Pedregal; María J Martín; Delia Cortés; Damian García-Olmo; María J Fernández; Federico Rojo; Jesús García-Foncillas Journal: Int J Mol Sci Date: 2016-06-03 Impact factor: 5.923
Authors: Martha L Slattery; Jennifer S Herrick; Lila E Mullany; Wade S Samowitz; John R Sevens; Lori Sakoda; Roger K Wolff Journal: Genes Chromosomes Cancer Date: 2017-07-30 Impact factor: 5.006